Catalyst Dossier · compiled by CeliA 🧫

Acadia Healthcare Company, Inc. (ACHC)

Services-Specialty Outpatient Facilities, NEC · market cap $2.3B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Acadia Healthcare (ACHC) is a for-profit behavioral health services operator running over 225 facilities — including 50+ inpatient psychiatric hospitals and 165 methadone clinics — across the US and Puerto Rico, with ~$3.3B in 2025 revenue. The company carries $2.4B in net debt against a $2.5B market cap, posted a net loss of ~$1.1B in 2025 after two prior profitable years, and faces a short interest of nearly 22% of float. The pipeline data listed appears misattributed from Acadia Pharmaceuticals rather than Acadia Healthcare's core services business.

The catalyst path

2026-08-04Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Pimavanserin tartrate	Phase 2	Alzheimer's Disease Psychosis
Pimavanserin	Phase 3	Neuropsychiatric Symptoms Related to Neurodegenerative Disease
ACP-103	Phase 2	Schizophrenia
ACP-204	Phase 3	Alzheimer's Disease Psychosis
Trofinetide	Phase 3	Rett Syndrome
pimavanserin tartrate (ACP-103)	Phase 3	Parkinson's Disease Psychosis

Price & technical context

3-month

+33.6%

6-month

+115.5%

12-month

+37.7%

52-wk range

$11.68–$31.25

vs 50-day MA

+21.7%

vs 200-day MA

+48.3%

Realized vol

65.5%

Max drawdown

-85.7%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ACHC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.